BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Dow
Deloitte
Merck
Healthtrust
Farmers Insurance
Chubb
Citi
AstraZeneca

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020381

« Back to Dashboard

NDA 020381 describes NIASPAN TITRATION STARTER PACK, which is a drug marketed by Abbvie and is included in one NDA. It is available from eight suppliers. There is one patent protecting this drug. Additional details are available on the NIASPAN TITRATION STARTER PACK profile page.

The generic ingredient in NIASPAN TITRATION STARTER PACK is niacin. There are fourteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the niacin profile page.
Summary for 020381
Tradename:NIASPAN TITRATION STARTER PACK
Applicant:Abbvie
Ingredient:niacin
Patents:2
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020381
Ingredient-typeNicotinic Acids
Medical Subject Heading (MeSH) Categories for 020381
Suppliers and Packaging for NDA: 020381
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381 NDA AbbVie Inc. 0074-3074 0074-3074-90 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0074-3074-90)
NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381 NDA AbbVie Inc. 0074-3074 0074-3074-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0074-3074-30)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength375MG
Approval Date:Jul 28, 1997TE:RLD:No
Patent:➤ SubscribePatent Expiration:May 27, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength500MG
Approval Date:Jul 28, 1997TE:ABRLD:Yes
Patent:➤ SubscribePatent Expiration:May 27, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
Patent:➤ SubscribePatent Expiration:May 27, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

Expired US Patents for NDA 020381

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-004 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-004 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Teva
Cerilliant
Johnson and Johnson
US Department of Justice
McKesson
Argus Health
Merck
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot